Correlation between self-reported Adherence to highly active antiretroviral therapy (HAART) and virologic outcomeDEMASI, Ralph A; GRAHAM, Neil M; TOLSON, Jerry M et al.Advances in therapy. 2001, Vol 18, Num 4, pp 163-173, issn 0741-238XArticle

Lack of recurrence of hyperlactatemia in HIV-infected patients switched from Stavudine to abacavir or zidovudineLONERGAN, J. Tyler; MCCOMSEY, Grace A; FISHER, Robin L et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 36, Num 4, pp 935-942, issn 1525-4135, 8 p.Article

Stavudine-associated peripheral neuropathy in zidovudine-naive patients: Effect of stavudine exposure and antiretroviral experienceSCARSELLA, Anthony; COODLEY, Gregg; SHALIT, Peter et al.Advances in therapy. 2002, Vol 19, Num 1, pp 1-8, issn 0741-238XArticle

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1 : Results of the TARGET studyHENRY, Keith; WALLACE, Robert J; BELLMAN, Paul C et al.The Journal of infectious diseases. 2001, Vol 183, Num 4, pp 571-578, issn 0022-1899Article

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. CommentaryMCCOMSEY, Grace A; PAULSEN, Denise M; ROSS, Steve T et al.AIDS (London). 2005, Vol 19, Num 1, pp 15-23, issn 0269-9370, 11 p.Article

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine : The results of the TARHEEL studyMCCOMSEY, Grace A; WARD, Douglas J; HOSSENTHALER, Siegrid M et al.Clinical infectious diseases. 2004, Vol 38, Num 2, pp 263-270, issn 1058-4838, 8 p.Article